Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 121 articles: HTML format

Single Articles

October 2025
1. AMIRMOKRI AJ, Loffredo CA, Makambi KH, Dawson NA, et al
   Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis.
   BMC Cancer. 2025;25:1645.
   PubMed     Abstract available
   
   
   
2. CHEN H, Chen J, Lyu F, Ma M, et al
   Comparison of the safety and efficacy of moderately hypofractionated and conventionally fractionated radiotherapy for localized prostate cancer: evidence from 9074 men in 13 randomized clinical trials.
   BMC Cancer. 2025;25:1634.
   PubMed     Abstract available
   
   
   
3. MAROTO JP, Puente J, Conde Moreno A, Juarez A, et al
   Real-world evidence in localized and locally advanced prostate cancer: applying artificial intelligence to electronic health records.
   BMC Cancer. 2025;25:1618.
   PubMed     Abstract available
   
   
   
4. ESMAELI M, Dehghanpour Dehabadi M
   Curcumin in prostate cancer: a systematic review of molecular mechanisms and nanoformulated therapeutic strategies.
   BMC Cancer. 2025;25:1609.
   PubMed     Abstract available
   
   
   
5. YEBOAH KO, Atawuchugi P, Baah FK, Petershie BE, et al
   The impact of zinc and testosterone co-treatment on tumourigenesis in prostate cancer: a novel model.
   BMC Cancer. 2025;25:1552.
   PubMed     Abstract available
   
   
   
6. GHOLIZADE M, Yazdani E, Hosseini-Baharanchi FS, Nikoofar A, et al
   Variations in radiomic features of the femoral head and neck during helical tomotherapy in prostate and rectal cancer patients.
   BMC Cancer. 2025;25:1509.
   PubMed     Abstract available
   
   
   
7. SEVEN D, Dalan AB, Bayrak OF
   Targeting GSTM3 for therapeutic potential in advanced prostate cancer.
   BMC Cancer. 2025;25:1493.
   PubMed     Abstract available
   
   
   
8. JIN L, Ma Z, Gao F, Li M, et al
   Automated machine learning for prostate cancer detection and Gleason score prediction using T2WI: a diagnostic multi-center study.
   BMC Cancer. 2025;25:1483.
   PubMed     Abstract available
   
   
   September 2025
9. KIM JK, Park MU, Lee D, Kim HJ, et al
   Sustained PSA screening is associated with downstaging and improved survival in prostate cancer: a 12-year Korean cohort study.
   BMC Cancer. 2025;25:1462.
   PubMed     Abstract available
   
   
   
10. JIN Y, Zhang Y, Wang M, Bai X, et al
    Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto((R))) in advanced prostate cancer: a disproportionality analysis based on the fda's adverse event reporting system (FAERS).
    BMC Cancer. 2025;25:1470.
    PubMed     Abstract available
    
    
    August 2025
11. ICER MA, Kocak T, Acar-Tek N, Yesil S, et al
    Serum neopterin and kynurenine as predictive and prognostic biomarkers in prostate cancer: the role of dietary inflammatory index and biomarker interactions.
    BMC Cancer. 2025;25:1395.
    PubMed     Abstract available
    
    
    
12. DENG S, Huang D, Han X, Zhang H, et al
    A novel MRI-based habitat analysis and deep learning for predicting perineural invasion in prostate cancer: a two-center study.
    BMC Cancer. 2025;25:1367.
    PubMed     Abstract available
    
    
    
13. CUI F, Zhang Y, Tang X, Gong D, et al
    Weight gain or loss after diagnosis and survival outcomes in prostate cancer: a meta-analysis.
    BMC Cancer. 2025;25:1286.
    PubMed     Abstract available
    
    
    
14. AHAMED Y, Hossain M, Baral S, Al-Raiyan AU, et al
    The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.
    BMC Cancer. 2025;25:1264.
    PubMed     Abstract available
    
    
    July 2025
15. ZHANG L, Li L, Zhe X, Tang M, et al
    Combination of PI-RADS version 2.1 and amide proton transfer values for the detection of clinically significant prostate cancer.
    BMC Cancer. 2025;25:1249.
    PubMed     Abstract available
    
    
    
16. SYED A, Raza H, Khaskheli HK, Rafique I, et al
    Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis.
    BMC Cancer. 2025;25:1173.
    PubMed     Abstract available
    
    
    
17. RAHBAR K, Schlack K, Bogemann M
    Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study.
    BMC Cancer. 2025;25:1159.
    PubMed    
    
    
    
18. BOEGEMANN M, Bennamoun M, Dourthe LM, Encarnacion JA, et al
    Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer.
    BMC Cancer. 2025;25:1119.
    PubMed     Abstract available
    
    
    
19. LIU D, Lin W, Wei C, Huang Y, et al
    Exploring the potential clinical value of shear wave elastography in prostate cancer: a meta-analysis.
    BMC Cancer. 2025;25:1032.
    PubMed     Abstract available
    
    
    
20. SUN C, Sun X, Chen Y, Wu Y, et al
    Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis.
    BMC Cancer. 2025;25:1042.
    PubMed     Abstract available
    
    
    June 2025
21. ZHANG G, Guo X, Zhu C, Li S, et al
    Association between serum 25-hydroxyvitamin D and prostate cancer in middle-aged and elderly Americans: a national population-based analysis of NHANES 2001-2018.
    BMC Cancer. 2025;25:1014.
    PubMed     Abstract available
    
    
    May 2025
22. SU R, Ye SJ, Wang SY, Zhang ZL, et al
    Ten-year follow-up of atypical small acinar hyperplasia cases diagnosed by initial prostate biopsy.
    BMC Cancer. 2025;25:964.
    PubMed     Abstract available
    
    
    
23. QI P, Zhao J, Zhang H, Liu X, et al
    TRPM2 channels mediate ROS-induced actin remodeling and cell migration of prostate cancer cells.
    BMC Cancer. 2025;25:956.
    PubMed     Abstract available
    
    
    
24. LIU Z, Gu WJ, Wan FN, Chen ZZ, et al
    Deep learning network enhances imaging quality of low-b-value diffusion-weighted imaging and improves lesion detection in prostate cancer.
    BMC Cancer. 2025;25:953.
    PubMed     Abstract available
    
    
    
25. CHAI L, Yao X, Yang X, Na R, et al
    Synthesizing [(18)F]PSMA-1007 PET bone images from CT images with GAN for early detection of prostate cancer bone metastases: a pilot validation study.
    BMC Cancer. 2025;25:907.
    PubMed     Abstract available
    
    
    
26. ZHAI J, Liu S, Wang T, Wang Y, et al
    Prognosis, immunological features and potential mechanisms of HKR1 in prostate cancer via single-cell and bulk RNA-sequencing.
    BMC Cancer. 2025;25:822.
    PubMed     Abstract available
    
    
    April 2025
27. QIU Y, Wang Y, Liu J, Sun K, et al
    Single-cell sequencing unveils the transcriptomic landscape of castration-resistant prostate cancer-associated fibroblasts and their association with prognosis and immunotherapy response.
    BMC Cancer. 2025;25:813.
    PubMed     Abstract available
    
    
    
28. WANG J, An H, Tao N
    Association of non-insulin-based insulin resistance indices, mean platelet volume and prostate cancer: a cross-sectional study.
    BMC Cancer. 2025;25:795.
    PubMed     Abstract available
    
    
    
29. HUANG Y, Wei C, Chen F, Zhang Y, et al
    Comparing the biopsy strategies of prostate cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:786.
    PubMed     Abstract available
    
    
    
30. FAN Z, Li D, Yan S, Zhao X, et al
    NEoAdjuvant radiohormonal therapy versus standard of care for oligometastatic prostate cancer (NEAR-TOP): study protocol of a multicenter, open-label, randomised controlled trial.
    BMC Cancer. 2025;25:768.
    PubMed     Abstract available
    
    
    
31. WANG N, Xu X, Zhong Y, Wan Y, et al
    MBs(NRP2)-based ultrasound molecular imaging for early diagnosis of castration-resistant prostate cancer.
    BMC Cancer. 2025;25:769.
    PubMed     Abstract available
    
    
    
32. KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al
    Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma.
    BMC Cancer. 2025;25:766.
    PubMed     Abstract available
    
    
    
33. WANG Y, Chang Y, Song L, Ren J, et al
    Robotic prostatectomy for large-volume prostates in prostate cancer: a retrospective analysis of 50 cases (>100 ml).
    BMC Cancer. 2025;25:701.
    PubMed     Abstract available
    
    
    
34. XU X, Fei W, Wu M, He Y, et al
    Construction and validation of a nomogram for identifying the patients at risk for rapid progression of advanced hormone-sensitive prostate cancer.
    BMC Cancer. 2025;25:634.
    PubMed     Abstract available
    
    
    
35. BONNEAU M, Steinmeyer Z, Morisseau M, Lozano S, et al
    Impact of comprehensive geriatric assessment on treatment decisions in older prostate cancer patients.
    BMC Cancer. 2025;25:642.
    PubMed     Abstract available
    
    
    
36. LU F, Zhao Y, Wang Z, Feng N, et al
    Biparametric MRI-based radiomics for prediction of clinically significant prostate cancer of PI-RADS category 3 lesions.
    BMC Cancer. 2025;25:615.
    PubMed     Abstract available
    
    
    
37. PANG Y, Li J, Hu H, Ung COL, et al
    Genetic associations of prostate cancer in China: a systematic review.
    BMC Cancer. 2025;25:604.
    PubMed     Abstract available
    
    
    March 2025
38. THOMSEN MT, Busk M, Zhang D, Chiu CL, et al
    The olfactory receptor OR51E2 regulates prostate cancer aggressiveness and modulates STAT3 in prostate cancer cells and in xenograft tumors.
    BMC Cancer. 2025;25:535.
    PubMed     Abstract available
    
    
    
39. WATANABE K, Kamitani N, Ikeda N, Kawata Y, et al
    Long-term outcomes of salvage high-dose-rate brachytherapy for localized recurrence of prostate cancer following definitive radiation therapy: a retrospective analysis.
    BMC Cancer. 2025;25:524.
    PubMed     Abstract available
    
    
    
40. SEKINE Y, Oka D, Ohtsu A, Nakayama H, et al
    The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo.
    BMC Cancer. 2025;25:521.
    PubMed     Abstract available
    
    
    
41. HUANG Z, Li G, Zhang Z, Gu R, et al
    Retraction Note: beta2AR-HIF-1alpha-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells.
    BMC Cancer. 2025;25:475.
    PubMed    
    
    
    
42. HUANG H, Wang T, Li W, Wu Z, et al
    Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.
    BMC Cancer. 2025;25:432.
    PubMed     Abstract available
    
    
    February 2025
43. SHENG T, Su H, Yao L, Qu Z, et al
    RhoB regulates prostate cancer cell proliferation and docetaxel sensitivity via the PI3K-AKT signaling pathway.
    BMC Cancer. 2025;25:354.
    PubMed     Abstract available
    
    
    
44. WANG L, Chen SY, Wan S, Li KP, et al
    Vasectomy and prostate cancer risk: a pooled of cohort studies and Mendelian randomization analysis.
    BMC Cancer. 2025;25:332.
    PubMed     Abstract available
    
    
    
45. WEN Y, Zhan S, Wang S, Yang L, et al
    LINC00657 exhibits oncogenic properties in prostate cancer and may serve as a prognostic biomarker in cancer.
    BMC Cancer. 2025;25:314.
    PubMed     Abstract available
    
    
    
46. WEGENER E, Ng M, Guerrieri M, Showalter TN, et al
    A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol.
    BMC Cancer. 2025;25:250.
    PubMed     Abstract available
    
    
    
47. CAO L, He R, Zhang A, Li L, et al
    Development of a deep learning system for predicting biochemical recurrence in prostate cancer.
    BMC Cancer. 2025;25:232.
    PubMed     Abstract available
    
    
    
48. FAN J, Xu K, Jiang Z, Gan C, et al
    Role of (18)F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study.
    BMC Cancer. 2025;25:192.
    PubMed     Abstract available
    
    
    January 2025
49. SCHUMACHER O, Newton RU, Tang C, Chee R, et al
    Exercise medicine as adjunct therapy during RADIation for CAncer of the prostaTE to improve treatment efficacy - protocol for the ERADICATE study: a phase II randomised controlled trial.
    BMC Cancer. 2025;25:160.
    PubMed     Abstract available
    
    
    
50. VAN DER STARRE CM, Bangma CH, Bijlsma MJ, van den Bergh ACM, et al
    External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study.
    BMC Cancer. 2025;25:149.
    PubMed     Abstract available
    
    
    
51. MAMMONE G, Borghesi S, Borsellino N, Calio A, et al
    Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies.
    BMC Cancer. 2025;25:127.
    PubMed     Abstract available
    
    
    
52. CHEN Z, Li Z, Dou R, Jiang S, et al
    Personalized optimization of systematic prostate biopsy core number based on mpMRI radiomics features: a large-sample retrospective analysis.
    BMC Cancer. 2025;25:116.
    PubMed     Abstract available
    
    
    
53. LIN TP, Chen PC, Lin CY, Wang BJ, et al
    Prostate cancer cells elevate glycolysis and G6PD in response to caffeic acid phenethyl ester-induced growth inhibition.
    BMC Cancer. 2025;25:95.
    PubMed     Abstract available
    
    
    
54. BOVELL AAN, Ramaliba T, Goodwin SO, Phillip JC, et al
    Incidence, trends and patterns of female breast, cervical, colorectal and prostate cancers in Antigua and Barbuda, 2017-2021: a retrospective study.
    BMC Cancer. 2025;25:72.
    PubMed     Abstract available
    
    
    
55. SHAHSHENAS S, Hosseini SM, Yarmohammadi H, Soltanipur M, et al
    Expression of cytokeratin 19 in prostatic adenocarcinoma: a systematic review.
    BMC Cancer. 2025;25:52.
    PubMed     Abstract available
    
    
    
56. LI D, Jian J, Shi M, Chen Z, et al
    Elevated miR-221-3p inhibits epithelial-mesenchymal transition and biochemical recurrence of prostate cancer via targeting KPNA2: an evidence-based and knowledge-guided strategy.
    BMC Cancer. 2025;25:34.
    PubMed     Abstract available
    
    
    December 2024
57. KIRLI BOLUKBAS M, Figen M, Kocak Uzel E
    Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey.
    BMC Cancer. 2024;24:1563.
    PubMed     Abstract available
    
    
    November 2024
58. LI C, Jing Z, Guo Q, Zheng Z, et al
    Causal roles of dietary structure and types on prostate cancer risk: A mendelian randomization study.
    BMC Cancer. 2024;24:1476.
    PubMed     Abstract available
    
    
    
59. WU XH, Ke ZB, Chen ZJ, Liu WQ, et al
    Periprostatic fat magnetic resonance imaging based radiomics nomogram for predicting biochemical recurrence-free survival in patients with non-metastatic prostate cancer after radical prostatectomy.
    BMC Cancer. 2024;24:1459.
    PubMed     Abstract available
    
    
    
60. SATO K, Sakamoto S, Saito S, Shibata H, et al
    Time-dependent personalized prognostic analysis by machine learning in biochemical recurrence after radical prostatectomy: a retrospective cohort study.
    BMC Cancer. 2024;24:1446.
    PubMed     Abstract available
    
    
    
61. MEHNERT E, Moller FS, Hofbauer C, Weidlich A, et al
    Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.
    BMC Cancer. 2024;24:1431.
    PubMed     Abstract available
    
    
    
62. NGOWI BN, Mremi A, Mbwambo OJ, Seventh F, et al
    Trend in incidence and clinicopathological characteristics of prostate cancer in Northern Tanzania: analysis from a population based cancer registry data 2015-2021.
    BMC Cancer. 2024;24:1424.
    PubMed     Abstract available
    
    
    
63. BAKENGA A, Natukunda B, Okuku F, Mubiru KR, et al
    Clinical characteristics and survival of patients with de novo metastatic prostate cancer treated with androgen deprivation therapy and taxane-based chemotherapy in Uganda: a retrospective study.
    BMC Cancer. 2024;24:1404.
    PubMed     Abstract available
    
    
    October 2024
64. SHAO IH, Chen SY, Chen HY, Sheng TW, et al
    Integrating clinical and image-based parameters for prediction of early post-prostatectomy incontinence recovery: simplified nomogram approach.
    BMC Cancer. 2024;24:1344.
    PubMed     Abstract available
    
    
    
65. SHAO YJ, Liao CS, Hsu YC, Chiu YC, et al
    Clinical relevance of protein-truncating variants of germline DNA repair genes in prostate cancer.
    BMC Cancer. 2024;24:1319.
    PubMed     Abstract available
    
    
    
66. SONG J, Sun X, Wang T, Li C, et al
    Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.
    BMC Cancer. 2024;24:1261.
    PubMed     Abstract available
    
    
    
67. LI X, Li Y, Zhang L, Long H, et al
    Single-cell sequencing analysis revealed that NEAT1 was a potential biomarker and therapeutic target of prostate cancer.
    BMC Cancer. 2024;24:1242.
    PubMed     Abstract available
    
    
    
68. ABIKAR A, Mustafa MMS, Athalye RR, Nadig N, et al
    Comparative transcriptome of normal and cancer-associated fibroblasts.
    BMC Cancer. 2024;24:1231.
    PubMed     Abstract available
    
    
    September 2024
69. ZHU Z, Zhu Y, Shi H, Zhou P, et al
    Efficacy of brachytherapy versus radical prostatectomy for localized prostate cancer-propensity score-matched comparison.
    BMC Cancer. 2024;24:1177.
    PubMed     Abstract available
    
    
    
70. DONG J, Ji R, Cui L, Liu G, et al
    Feasibility, safety and effectiveness of robot-assisted radical prostatectomy with a new robotic surgical system: a prospective, controlled, randomized clinical trial.
    BMC Cancer. 2024;24:1194.
    PubMed     Abstract available
    
    
    
71. SHEN C, Zhu X, Chen Z, Zhang W, et al
    Nomogram predicting early urinary incontinence after radical prostatectomy.
    BMC Cancer. 2024;24:1095.
    PubMed     Abstract available
    
    
    August 2024
72. XIAO Y, Lai C, Hu J, Mulati Y, et al
    Integrative analysis regarding the correlation between collagen-related genes and prostate cancer.
    BMC Cancer. 2024;24:1038.
    PubMed     Abstract available
    
    
    
73. GARG R, Williamson M
    The metastasis-promoting P1597L mutation in PlexinB1 enhances Ras activity.
    BMC Cancer. 2024;24:1004.
    PubMed     Abstract available
    
    
    
74. WANG Q, Ketteler S, Bagheri S, Ebrahimifard A, et al
    Diagnostic efficacy of [(99m)Tc]Tc-PSMA SPECT/CT for prostate cancer: a meta-analysis.
    BMC Cancer. 2024;24:982.
    PubMed     Abstract available
    
    
    
75. MURPHY K, Kehoe B, Denieffe S, McGrath A, et al
    'Just because I have prostate cancer doesn't mean that I can't do things' - men's experiences of the acceptability of an exercise intervention for prostate cancer during treatment.
    BMC Cancer. 2024;24:949.
    PubMed     Abstract available
    
    
    
76. JANORAY G, Bruguiere E, Mazurier J, Dudouet P, et al
    Long-term evaluation of the safety of a rectal-prostate spacer, the ProSpace(R) balloon, in patients treated with radiotherapy for prostate cancer.
    BMC Cancer. 2024;24:934.
    PubMed     Abstract available
    
    
    July 2024
77. LEE J, Hong J, Kim JW, Lim S, et al
    Investigating miR-6880-5p in extracellular vesicle from plasma as a prognostic biomarker in endocrine therapy-treated castration-resistant prostate cancer.
    BMC Cancer. 2024;24:909.
    PubMed     Abstract available
    
    
    
78. SUN W, Li H, Shi W, Lv Q, et al
    Associations between genetically predicted concentrations of plasma proteins and the risk of prostate cancer.
    BMC Cancer. 2024;24:905.
    PubMed     Abstract available
    
    
    
79. WANG Z, Liu H, Zhu Q, Chen J, et al
    Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    BMC Cancer. 2024;24:817.
    PubMed     Abstract available
    
    
    
80. KIM JS, Taaffe DR, Galvao DA, Clay TD, et al
    Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study.
    BMC Cancer. 2024;24:784.
    PubMed     Abstract available
    
    
    June 2024
81. HUANG J, Sun J, Wang K, Zheng L, et al
    Causal relationship between prostatic diseases and prostate cancer: a mendelian randomization study.
    BMC Cancer. 2024;24:774.
    PubMed     Abstract available
    
    
    
82. CI X, Chen S, Zhu R, Zarif M, et al
    Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer.
    BMC Cancer. 2024;24:744.
    PubMed     Abstract available
    
    
    
83. YANG J, Xu Z, Zheng W, Li Y, et al
    Identification of the cytoplasmic DNA-Sensing cGAS-STING pathway-mediated gene signatures and molecular subtypes in prostate cancer.
    BMC Cancer. 2024;24:732.
    PubMed     Abstract available
    
    
    
84. XU X, Wang W, He Y, Yao Y, et al
    Prognostic marker VPS72 could promote the malignant progression of prostate cancer.
    BMC Cancer. 2024;24:713.
    PubMed     Abstract available
    
    
    
85. ZHU Q, Chen J, Liu H, Zhao J, et al
    The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
    BMC Cancer. 2024;24:706.
    PubMed     Abstract available
    
    
    
86. CHENG TS, Noor U, Watts E, Pollak M, et al
    Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition.
    BMC Cancer. 2024;24:676.
    PubMed     Abstract available
    
    
    May 2024
87. FU L, Zhang C, Wang Z, Tao W, et al
    Clinical application of serum tumor abnormal protein in prostate cancer patients.
    BMC Cancer. 2024;24:665.
    PubMed     Abstract available
    
    
    
88. WANG B, Pan J, Zhang T, Ni X, et al
    Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen
    BMC Cancer. 2024;24:643.
    PubMed     Abstract available
    
    
    
89. CUI F, Tang X, Man C, Fan Y, et al
    Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis.
    BMC Cancer. 2024;24:628.
    PubMed     Abstract available
    
    
    
90. CHE B, Yuan S, Zhang H, Zhai J, et al
    Causal inference between pernicious anemia and cancers: a bidirectional two-sample mendelian randomization analysis.
    BMC Cancer. 2024;24:586.
    PubMed     Abstract available
    
    
    
91. OBINATA D, Takayama K, Lawrence MG, Funakoshi D, et al
    Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
    BMC Cancer. 2024;24:554.
    PubMed     Abstract available
    
    
    April 2024
92. IHEANACHO CO, Enechukwu OH
    Role of antihypertensive medicines in prostate cancer: a systematic review.
    BMC Cancer. 2024;24:542.
    PubMed     Abstract available
    
    
    
93. YANG L, Ruan Y, Xu H
    HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis.
    BMC Cancer. 2024;24:544.
    PubMed     Abstract available
    
    
    
94. COLETTA AM, Simon LH, Maslana K, Taylor S, et al
    Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
    BMC Cancer. 2024;24:493.
    PubMed     Abstract available
    
    
    
95. LIU HE, Vuppalapaty M, Hoerner CR, Bergstrom CP, et al
    Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate c
    BMC Cancer. 2024;24:482.
    PubMed     Abstract available
    
    
    
96. YOU X, Qiu J, Li Q, Zhang Q, et al
    Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway.
    BMC Cancer. 2024;24:472.
    PubMed     Abstract available
    
    
    
97. DUAN L, Liu Z, Wan F, Dai B, et al
    Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects.
    BMC Cancer. 2024;24:448.
    PubMed     Abstract available
    
    
    
98. FREDMAN E, Icht O, Moore A, Bragilovski D, et al
    SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
    BMC Cancer. 2024;24:431.
    PubMed     Abstract available
    
    
    
99. AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
    Correction: Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.
    BMC Cancer. 2024;24:419.
    PubMed    
    
    
    March 2024
100. GUZMAN J, Weigelt K, Neumann A, Tripal P, et al
     NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers.
     BMC Cancer. 2024;24:346.
     PubMed     Abstract available
     
     
     
101. SHEN Z, Yao C, Bai Y, Wang Y, et al
     Transversal approach via a bladder neck and prostate combined longitudinal incision versus standard approach of robotic-assisted radical prostatectomy for localized prostate cancer: a retrospective analysis.
     BMC Cancer. 2024;24:313.
     PubMed     Abstract available
     
     
     
102. CUI F, Qiu Y, Xu W, Zou C, et al
     Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis.
     BMC Cancer. 2024;24:305.
     PubMed     Abstract available
     
     
     
103. MIYAZAWA Y, Koike H, Oka D, Kawamura H, et al
     Comparison of sexual function after robot-assisted radical prostatectomy and carbon-ion radiotherapy for Japanese prostate cancer patients using propensity score matching.
     BMC Cancer. 2024;24:300.
     PubMed     Abstract available
     
     
     
104. FU Q, Luo L, Hong R, Zhou H, et al
     Radiogenomic analysis of ultrasound phenotypic features coupled to proteomes predicts metastatic risk in primary prostate cancer.
     BMC Cancer. 2024;24:290.
     PubMed     Abstract available
     
     
     
105. KHALIL MIM, Ashour A, Shaala RS, Allam RM, et al
     Effect of health belief model-based educational intervention on prostate cancer prevention; knowledge, practices, and intentions.
     BMC Cancer. 2024;24:289.
     PubMed     Abstract available
     
     
     February 2024
106. HUANG H, Liu Y, Wen Z, Chen C, et al
     Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis.
     BMC Cancer. 2024;24:261.
     PubMed     Abstract available
     
     
     
107. CHEN J, Yu F, He G, Hao W, et al
     A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.
     BMC Cancer. 2024;24:254.
     PubMed     Abstract available
     
     
     
108. FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
     Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
     BMC Cancer. 2024;24:191.
     PubMed     Abstract available
     
     
     January 2024
109. LING SW, van der Veldt AAM, Konijnenberg M, Segbers M, et al
     Evaluation of the tolerability and safety of [(225)Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
     BMC Cancer. 2024;24:146.
     PubMed     Abstract available
     
     
     
110. WANG J, Liu J, Yuan C, Yang B, et al
     Palmitic acid-activated GPRs/KLF7/CCL2 pathway is involved in the crosstalk between bone marrow adipocytes and prostate cancer.
     BMC Cancer. 2024;24:75.
     PubMed     Abstract available
     
     
     
111. ENKE JS, Gross M, Grosser B, Sipos E, et al
     SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
     BMC Cancer. 2024;24:65.
     PubMed     Abstract available
     
     
     
112. MULATI Y, Lai C, Luo J, Hu J, et al
     Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer.
     BMC Cancer. 2024;24:44.
     PubMed     Abstract available
     
     
     
113. ZHAO S, Miao M, Wang Q, Zhao H, et al
     The current status of clinical trials on cancer and age disparities among the most common cancer trial participants.
     BMC Cancer. 2024;24:30.
     PubMed     Abstract available
     
     
     
114. ZHOU X, Chai K, Zhu H, Luo C, et al
     The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target.
     BMC Cancer. 2024;24:8.
     PubMed     Abstract available
     
     
     December 2023
115. DAI X, Shi X, Luo M, Li P, et al
     Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
     BMC Cancer. 2023;23:1241.
     PubMed     Abstract available
     
     
     
116. GUAN A, Santiago-Rodriguez EJ, Chung BI, Shim JK, et al
     Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.
     BMC Cancer. 2023;23:1191.
     PubMed     Abstract available
     
     
     November 2023
117. HASANI M, Alinia SP, Khazdouz M, Sobhani S, et al
     Oxidative balance score and risk of cancer: a systematic review and meta-analysis of observational studies.
     BMC Cancer. 2023;23:1143.
     PubMed     Abstract available
     
     
     
118. CHEN Z, Zhang J, Jin D, Wei X, et al
     A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score.
     BMC Cancer. 2023;23:1138.
     PubMed     Abstract available
     
     
     October 2023
119. HUANG L, Ma B, Zhang C, Shi J, et al
     Unveiling poly(rC)-binding protein 2 as the target protein for curcusone C against prostate cancer: mechanism validation through click chemistry-activity based proteomics profiling approach.
     BMC Cancer. 2023;23:957.
     PubMed     Abstract available
     
     
     
120. AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
     Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.
     BMC Cancer. 2023;23:927.
     PubMed     Abstract available
     
     
     September 2023
121. WOLFE S, Diven MA, Marciscano AE, Zhou XK, et al
     A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
     BMC Cancer. 2023;23:923.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.